This article has not been clinically reviewed.
Educational only: This article provides general information and is not an offer to prescribe, dispense, or sell medication. Current weight-management programs, pricing, and availability are listed on our weight management page. Availability varies by state, and a licensed clinician decides whether any treatment is appropriate.
Semaglutide and tirzepatide: how they differ
Semaglutide and tirzepatide are prescription medications that may be used for certain metabolic or weight-management indications, depending on the specific product, approved labeling, and a patient’s clinical eligibility. They are not interchangeable, and a licensed clinician must determine whether either medication is appropriate.
Semaglutide targets the glucagon-like peptide-1 (GLP-1) receptor. Tirzepatide targets both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. This difference in receptor activity is one reason clinicians may consider different clinical histories, treatment goals, tolerability, and approved uses when evaluating a medication.
What patients should discuss with a clinician
A prescribing decision should consider your health history, current medications, prior treatment response, contraindications, and any necessary laboratory review. Do not start, stop, switch, or change the dose of a prescription medication without guidance from a qualified healthcare professional.
Potential side effects and precautions
Common adverse effects can include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. More serious complications can occur. Seek prompt medical guidance for severe, persistent, or concerning symptoms. A clinician or pharmacist should review the complete prescribing information and your individual risk factors with you.
Semaglutide or tirzepatide — your physician decides with you.
Revelry physicians evaluate your BMI, health history, and goals to recommend the right GLP-1 and starting dose. Not a vending machine — actual clinical oversight.
View Weight Loss Programs →Medication choice, dose escalation, monitoring, and follow-up are clinical decisions. Individual response varies, and no particular outcome can be guaranteed.
Educational disclaimer
This article is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. It does not create a clinician-patient relationship. Consult a qualified healthcare professional about your own health circumstances. If you think you are experiencing a medical emergency, call 911.
Medical disclaimer: This article is for educational purposes only and is not medical advice. A licensed clinician determines whether treatment is appropriate. Availability varies by state. Call 911 for emergencies.
Physician-supervised GLP-1 programs.
Semaglutide and tirzepatide programs with ongoing physician monitoring, dose adjustment, and lab-guided care.
Browse Weight Loss Programs →